Contrasting effects of chronic hypoxia and nitric oxide synthase inhibition on circulating angiogenic factors in a rat model of growth restriction

American Journal of Obstetrics and Gynecology

Volumn 196, Issue 1, 2007, Pages 72.e1-72.e6

  Bahtiyar, Mert Ozan ^a   Buhimschi, Catalin ^a   Ravishankar, Viswanathan ^b   Copel, Joshua ^a   Norwitz, Errol ^a   Julien, Svena ^c   Guller, Seth ^a   Buhimschi, Irina A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

blood; hypoxia; NG nitro L arginine methyl ester; placental growth factor; rat soluble fms like tyrosine kinase 1; vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; OXYGEN; PLACENTAL GROWTH FACTOR; SODIUM CHLORIDE; VASCULOTROPIN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DEATH; ENZYME INHIBITION; FEMALE; GESTATIONAL AGE; HYPOTHESIS; HYPOXIA; IMMUNOASSAY; INTRAUTERINE GROWTH RETARDATION; LABOR ONSET; MATERNAL BLOOD; MATERNAL SERUM; NONHUMAN; NULLIPARA; OSMOTIC MINIPUMP; OSMOTIC PUMP; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

EID: 33846192815     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2006.07.048     Document Type: Article

References (30)

1. Ergaz Z., Avgil M., and Ornoy A. Intrauterine growth restriction-etiology and consequences: what do we know about the human situation and experimental animal models?. Reprod Toxicol 20 (2005) 301-322
2. Dombrowski M.P., Schatz M., Wise R., et al. Asthma during pregnancy. Obstet Gynecol 103 (2004) 5-12
3. Vigil-De Gracia P., Montufar-Rueda C., and Smith A. Pregnancy and severe chronic hypertension: maternal outcome. Hypertens Pregnancy 23 (2004) 285-293
4. Chesley L. A short history of eclampsia. Obstet Gynecol 43 (1974) 559-602
5. Fisher S.J. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2 (2004) 53
6. Buhimschi C.S., Norwitz E.R., Funai E., et al. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia. Am J Obstet Gynecol 192 (2005) 734-741
7. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. [see comment]. N Engl J Med 350 (2004) 672-683
8. Buhimschi C., Magloire L., Funai E., et al. Fractional excretion of angiogenic factors in women with severe preeclampsia. Obstet Gynecol 107 (2006) 1103-1113
9. Maynard S.E., Min J.-Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. [see comment]. J Clin Invest 111 (2003) 649-658
10. Sugimoto H., Hamano Y., Charytan D., et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 278 (2003) 12605-12608
11. Buhimschi I.A., Saade G.R., Chwalisz K., and Garfield R.E. The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update 4 (1998) 25-42
12. Yallampalli C., and Garfield R.E. Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. Am J Obstet Gynecol 169 (1993) 1316-1320
13. Molnar M., Suto T., Toth T., and Hertelendy F. Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am J Obstet Gynecol 170 (1994) 1458-1466
14. Buhimschi C.S., Gokdeniz R., Saade G.R., Buhimschi I.A., and Garfield R.E. The effect of chronic nitric oxide synthase inhibition on blood pressure and heart rate in unrestrained pregnant rats as recorded by radiotelemetry. Am J Obstet Gynecol 181 (1999) 159-164
15. Thaete L.G., Neerhof M.G., and Caplan M.S. Endothelin receptor A antagonism prevents hypoxia-induced intrauterine growth restriction in the rat. Am J Obstet Gynecol 176 (1997) 73-76
16. Reynolds L.P., Borowicz P.P., Vonnahme K.A., et al. Animal models of placental angiogenesis. Placenta 26 (2005) 689-708
17. Lyall F., Greer I.A., Boswell F., and Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. BJOG 104 (1997) 223-228
18. Gerber H.P., McMurtrey A., Kowalski J., et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway: requirement for Flk-1/KDR activation. J Biol Chem 273 (1998) 30336-30343
19. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., and Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5 (1991) 1806-1814
20. Greb R.R., Heikinheimo O., Williams R.F., Hodgen G.D., and Goodman A.L. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum Reprod 12 (1997) 1280-1292
21. Mesiano S., Chan E.-C., Fitter J.T., Kwek K., Yeo G., and Smith R. Progesterone withdrawal and estrogen activation in human parturition are coordinated by progesterone receptor A expression in the myometrium. J Clin Endocrinol Metabol 87 (2002) 2924-2930
22. Krauss T., Pauer H.-U., and Augustin H.G. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 23 (2004) 101-111
23. Vonnahme K.A., Wilson M.E., and Ford S.P. Relationship between placental vascular endothelial growth factor expression and placental/endometrial vascularity in the pig. Biol Reprod 64 (2001) 1821-1825
24. Buhimschi I., Yallampalli C., Chwalisz K., and Garfield R.E. Pre-eclampsia-like conditions produced by nitric oxide inhibition: effects of L-arginine, D-arginine and steroid hormones. Hum Reprod 10 (1995) 2723-2730
25. Mayr A.J., Lederer W., Wolf H.J., Dunser M., Pfaller K., and Mortl M.G. Morphologic changes of the uteroplacental unit in preeclampsia-like syndrome in rats. Hypertens Pregnancy 24 (2005) 29-37
26. Thaete L.G., Kushner D.M., Dewey E.R., and Neerhof M.G. Endothelin and the regulation of uteroplacental perfusion in nitric oxide synthase inhibition-induced fetal growth restriction. Placenta 26 (2005) 242-250
27. Kimura H., and Esumi H. Reciprocal regulation between NO and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol 50 (2003) 49-59
28. Isenberg J. Nitric oxide modulation of early angiogenesis. Microsurgery 24 (2004) 385-391
29. Sellman J., DeRuisseau K., Betters J., et al. In vivo inhibition of nitric oxide synthase impairs upregulation of contractile protein mRNA in overloaded plantaris muscle. J Appl Physiol 100 (2006) 258-265
30. Buhimschi C., Buhimschi I., Yallampalli C., Chwalisz K., and Garfield R.E. Contrasting effects of diethylenetriamine-nitric oxide, a spontaneously releasing nitric oxide donor, on pregnant rat uterine contractility in vitro versus in vivo. Am J Obstet Gynecol 177 (1997) 690-701